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Fibroblast growth factor 23 (FGF23) is a circulating protein
that regulates the renal reabsorption of phosphate and also
inhibits 1-a-hydroxylase production. In adults FGF23 is
increased in chronic kidney disease (CKD) and is an important
prognostic factor for cardiovascular morbidity. In order to
gain insight into the role of FGF23 and other biochemical
variables of bone metabolism in children we studied 69
patients at different stages of CKD. FGF23 was found to be
significantly elevated in stage 3 compared with stages 1 and
2 of CKD, preceding significant hyperphosphatemia in stage
4 disease. The highest levels of FGF23 were found in stage 5
compared with stages 1 and 2 CKD. The levels of FGF23
positively correlated with parathyroid hormone and
phosphate concentrations and negatively with 1,25-
dihydroxyvitamin D, the estimated glomerular filtration
rate, and tubular phosphate reabsorption. Using multivariate
analysis, hyperphosphatemia and low estimated glomerular
filtration rate remained the most significant factors. Thus we
found that FGF23 likely has an important role in pediatric
calcium and phosphate homeostasis, and in vitamin D
metabolism, even at an early stage of CKD. Further studies
are needed to clarify the role of FGF23 on the pathogenesis
of renal osteodystrophy and its impact on cardiovascular
morbidity in pediatric patients with CKD.
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Fibroblast growth factors are polypeptide growth factors with
diverse biological activities, secreted into circulation with a
paracrine and/or autocrine mode of action. They are required
in multiple developmental processes including differentia-
tion, cell proliferation, and migration. FGF23 knockout mice
showing growth retardation and abnormal phosphate-
vitamin D metabolism also gradually die in the postnatal
stages.1
Fibroblast growth factor 23 (FGF23) is a circulating
phosphaturic factor that has an important role in the
regulation of inorganic phosphate homeostasis. It is a 227
amino-acid protein with a molecular weight of 25 kDa, which
is largely produced by osteocytes.2 It binds to a family of FGF
receptors, likely requiring the transmembrane protein klotho
to facilitate cell surface interaction.3 FGF receptors are
ubiquitously expressed, but the most important effects of
FGF23 have been described on the kidney and the
parathyroid gland.4
FGF23 contains a signal peptide and is secreted into the
circulation. Interacting with its renal receptors (and klotho),
FGF23 inhibits the type IIa and type IIc sodium phosphate
co-transporter (NaPi2a/NaPi2c) in the renal proximal
tubules and causes phosphaturia.5–8 In addition, FGF23
suppresses renal 1-a-hydroxylase expression, preventing 1,25-
dihydroxyvitamin D production by the kidneys and thereby
decreasing the small-bowel absorption of calcium and
inorganic phosphate.9
Consequently, hypophosphatemia, caused by urinary
phosphate wasting, reduced 1,25-dihydroxyvitamin D levels,
and osteomalacia are the main characteristics of disorders
with increased FGF23 levels, such as tumor-induced
osteomalacia10 and X-linked hypophosphatemic rickets.11,12
Mutations on the other hand, either in FGF2313 or in its
klotho coreceptor,14 lead to severe tumoral calcinosis
characterized by hyperphosphatemia, increased 1,25-dihy-
droxyvitamin D levels, and ectopic calcification.
Several other FGF23 effects are less well defined or proven.
As clinical studies in adults show, FGF23 may increase the
synthesis and release of parathyroid hormone (PTH) and
might be a predictor of future secondary hyperparathyroid-
ism in patients on dialysis treatment.3,15,16 Some evidence
suggests that PTH may stimulate FGF23 levels as well. Bone
mineralization may also be directly depressed by FGF23 in
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adult chronic kidney disease (CKD) patients.15 Data on
children are very scarce; only one study of serum FGF23 in
children on peritoneal dialysis has been published, in which
no correlation with PTH levels 4400 pg/ml could be shown,
but FGF23 levels were correlated with decreased osteoid
thickness and shorter osteoid maturation time on bone
biopsy.17
Excessive FGF23 and a deficiency of 1,25-dihydroxyvita-
min D are associated with increased mortality in CKD
patients.18 Furthermore, Gutie´rrez et al.18 have indicated that
FGF23 in adult CKD patients may be a better biomarker for
risk assessment than serum phosphate levels. In addition,
FGF23 toxicity might contribute to renal death.19
Thus, FGF23 has an important role in altered calcium-
phosphate homeostasis in adults with CKD and is viewed as a
risk factor for both vascular complications and renal
dysfunction.19–21 As no data on serum FGF23 in children
across the spectrum of CKD are available, we performed a
cross-sectional analysis in pediatric patients treated at our
institution.
RESULTS
The baseline demographic and clinical characteristics of the
CKD cohort are reported in Table 1. Analysis of the
biochemical variables in the respective study groups is
presented in Table 2.
FGF23, PTH, and phosphate homeostasis
There was a statistically significant increase in the levels of
FGF23 and PTH across the various stages of renal dysfunc-
tion (Figures 1 and 2).
In normal controls, FGF23 serum levels were 42.9
(±9.4) ng/l. Children with CKD stage 1–2 showed a mean
(±s.d.) FGF23 serum level of 47 (±26) ng/l and a serum
PTH level of 67 (±47) ng/l. No statistically significant
difference was noticed between CKD stage 1–2 patients and
the control patients regarding FGF23 levels and the variables
of bone metabolism and calcium-phosphate homeostasis.
CKD stage 3 patients showed a FGF23 serum level of 144
(±91) ng/l and a PTH serum level of 202 (±148) ng/l. In
patients with CKD stage 4, FGF23 serum levels were 313
(±275) ng/l and PTH serum levels were 308 (±220) ng/l.
Children on dialysis (CKD stage 5) showed a FGF23 serum
level of 734 (±397) ng/l and a serum PTH level of 425
(±371) ng/l. Serum phosphate levels showed a significant
increase only in CKD stage 4 and 5 patients relative to
CKD 1–2 (Po0.001; Figure 3). FGF23 serum levels in CKD
stage 5 did not differ significantly between hemodialysis
and peritoneal dialysis; also residual renal function had
no effect.
Serum concentrations of FGF23 correlated negatively with
estimated glomerular-filteration rate (eGFR; r¼0.57,
Po0.001; Figure 4). A positive correlation was found
between FGF23 serum levels and serum phosphate levels
(r¼ 0.56, Po0.001; Figure 5).
In addition, there was a positive correlation between
FGF23 and PTH serum levels in the combined group of CKD
(r¼ 0.26, P¼ 0.04) and serum FGF23 levels correlated
negatively with serum 1,25-dihydroxyvitamin D levels
(r¼0.61, Po0.001; Figure 6). Lastly, there was a negative
correlation between tubular phosphate reabsorption and
FGF23 (r¼0.48, Po0.001; Figure 7).
Table 1 | Baseline demographic and clinical characteristics of
the pediatric CKD cohort
N (%)
Gender
Male 45 65
Female 24 35
Causes of kidney disease
Congenital anomalies of kidney and urinary tract 20 28
Congenital nephropathies 12 17
Glomerulonephritis 11 16
Hemolytic uremic syndrome 5 7
Cystic renal disease 13 19
Other 7 13
Medication
Calcium carbonate 7 10
Sevelamer 13 19
25-Hydroxyvitamin D 26 38
1,25-Dihydroxyvitamin D 37 54
Abbreviation: CKD, chronic kidney disease.
Table 2 | Biochemical and urinary variables according to levels of renal function
Parameter (mean±s.d.) CKD 1–2 eGFR 460 (n=26) CKD 3 eGFR 30–59 (n=7) CKD 4 eGFR 15–29 (n=11) CKD 5 eGFRo15 (n=25)
Creatinine (mg/dl) 0.83±0.43 1.61±0.66** 3.18±1.18*** 7.63±2.68***
eGFR (ml/min per 1.73m2) 113±51 41±8*** 27±7*** 10±2***
Calcium (mmol/l) 2.34±0.12 2.41±0.14y 2.38±0.11y 2.31±0.37y
Phosphate (mmol/l) 1.27±0.25 1.43±0.19y 1.62±0.22*** 2.01±0.44***
TPR (%) 83.5±10.8 73.7±7.6* 56.7±18.0*** 38.9±28.9***
25(OH)D3 (mg/l) 21.0±11.8 31.2±17.9y 27.1±13.1y 24.3±9.4y
1,25(OH)2D3 (mg/l) 49.4±18.1 50±41.0
y 36.8±45.7** 30.9±39.8***
PTH (ng/l) 67±47 202±148* 308±220*** 425±371***
FGF23 (ng/l) 47±26 144±91** 313±275*** 734±397***
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate (expressed as ml/min per 1.73m2); FGF23, fibroblast growth factor 23; PTH, parathyroid
hormone; TPR, renal tubular phosphate reabsorption; 25(OH)D3, 25-dihydroxyvitamin D; 1,25(OH)2D3, 1,25-dihydroxyvitamin D.
Statistical difference of CKD stage 1–2 compared with CKD stages 3, 4, and 5, indicated as P-value (ynot significant, *Po0.05; **Pp0.01; ***Pp0.001).
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In the multivariate analysis, serum phosphate levels,
eGFR, and serum 1,25-dihydroxyvitamin D levels were
associated with FGF23 levels; serum PTH levels tended to
show a significant association (Table 3).
Vitamin D metabolism
Of 61 children, with data on 25-hydroxyvitamin D levels, 26
(42.6%) had vitamin D deficiency (o20 ng/ml) and 21
children (34.4%) showed relative vitamin D insufficiency
(20–30 ng/ml). None of them had severe deficiency with 25-
hydroxyvitamin D levels below 5 ng/ml.22 There was no
correlation between 25-hydroxyvitamin D levels and eGFR or
the biochemical variables of bone metabolism.
In contrast, serum 1,25-dihydroxyvitamin D levels showed
a significant negative correlation with FGF23 (r¼0.61,
Po0.001) and PTH levels (r¼0.48, Po0.001). Simulta-
neous to the relevant increase of serum FGF23 levels in CKD
stage 4 and 5, we could document a significant decrease of
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Figure 1 | Increase in serum fibroblast growth factor 23
(FGF23) levels with advanced chronic kidney disease (CKD)
stage. **Po0.01 CKD 1–2 vs. CKD 3, ***Po0.001 CKD 1–2 vs.
CKD 4, ***Po0.001 CKD 1–2 vs. CKD 5. Boxes and bars represent
the interquartile range and the median value, respectively;
whiskers represent the distance to the smallest and largest
unbooked sample value.
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Figure 2 | Increase in serum parathyroid hormone (PTH) levels
with advanced chronic kidney disease (CKD) stages. *Po0.05
CKD 1–2 vs. CKD 3, ***Po0.001 CKD 1–2 vs. CKD 4, ***Po0.001
CKD 1–2 vs. CKD 5. Boxes and bars represent the interquartile
range and the median value, respectively; whiskers represent the
distance to the smallest and largest unbooked sample value.
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Figure 3 | Increase in serum phosphate levels with advanced
chronic kidney disease (CKD) stages. ***P¼ 0.001 CKD 1–2 vs.
CKD 4, ***Po0.001 CKD 1–2 vs. CKD 5. Boxes and bars represent
the interquartile range and the median value, respectively;
whiskers represent the distance to the smallest and largest
unbooked sample value.
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Figure 4 |Correlation of serum fibroblast growth factor 23
(FGF23) levels with estimated growth factor rate (r¼0.57,
Po0.001).
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Figure 5 |Correlation of serum fibroblast growth factor 23
(FGF23) levels with serum phosphate levels (r¼ 0.56, Po0.001).
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1,25-dihydroxyvitamin D levels in these stages of renal failure
compared with CKD stage 1–2.
FGF23 levels were independent of age in all CKD stages
and in the control patients.
DISCUSSION
This is the first study assessing FGF23 serum levels in all
stages of CKD in children. In accordance with earlier studies
of adult patients, we were able to show that FGF23 levels
increase gradually with CKD and are already significantly
elevated in CKD stage 3. This increase is highly correlated
with hyperphosphatemia, with the degree of renal dysfunc-
tion, and with deficiency of 1,25-dihydroxyvitamin D.
Our data extend the findings of the study by Wesseling-
Perry et al.,17 who analyzed children on peritoneal dialysis
with hyperparathyroidism 4400 pg/ml with a different
FGF23 assay. Because of this kind of patient selection, they
could not show a correlation between PTH and FGF23 as in
our study. However, they very well showed a decreased
osteoid thickness in patients with high FGF23 levels. Thus,
future studies may delineate more specific mechanisms of
altered FGF23/PTH-induced bone pathology in CKD,
possibly even at early stages.
Several recent studies in adults have elaborated different
threshold levels at which glomerular filtration rate FGF23
levels show a significant increase. Our data indicate that a
significant elevation occurs already below an eGFR of 60 ml/
min per 1.73 m2. Shigematsu et al.23 found a rise in FGF23
levels at an eGFR below 30–80 ml/min per 1.73 m2, Gutie´rrez
et al.16 suggested a cut-off-level of 60 ml/min per 1.73 m2,
whereas Westerberg et al.24 showed that FGF23 levels do not
change until CKD stage 4 (eGFR o30 ml/min per 1.73 m2).
Owing to these different findings, the various methods used
to measure the eGFR make it difficult to estimate its
influence correctly. This may also relate to a few patients with
overt hyperfiltration as calculated by creatinine clearance.
Nevertheless, despite such differences in the exact time-
line, we can also show an elevation of FGF23 in the early
stages of CKD, which reaches significance starting from CKD
stage 3. Whether age-related factors have an additional role
has to be evaluated in further studies.
The role of FGF23 in phosphate metabolism of individuals
with normal renal function has recently been investigated.
Antoniucci et al.25 showed an immediate phosphaturic
response after phosphate load without changes in FGF23.
In contrast, Isakova et al.26 illustrated that longer periods of
high phosphate intake lead to an increase in FGF23
production. Another study described that FGF23 increases
with the rate of phosphate intake.27 No data on children
reflecting phosphate homeostasis with special regard to
FGF23 in CKD are available.
Regarding the effect of FGF23 on phosphate homeostasis
in CKD, our pediatric study could show a positive correlation
of FGF23 with serum phosphate levels and could confirm
serum phosphate levels as the strongest predictor of FGF23
elevation. As in adult CKD patients, a first significant increase
in phosphate levels occurred in CKD stage 4. On the other
hand, upregulation of FGF23 was already shown in CKD
stage 3. This supports the concept that FGF23 mitigates
hyperphosphatemia in chronic renal failure because FGF23
elevation precedes hyperphosphatemia.16 This is supported
by the negative correlation between FGF23 and tubular
phosphate reabsorption.
In vitro and in vivo studies have shown that FGF23 reduces
serum levels of 1,25-dihydroxyvitamin D by suppressing the
expression of the key converting enzyme 1-a-hydroxylase. In
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Figure 6 | Inverse correlation of serum fibroblast growth
factor 23 (FGF23) levels with serum 1,25-dihydroxyvitamin D
levels (r¼0.61, Po0.001).
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Figure 7 | Inverse correlation of serum fibroblast growth
factor 23 (FGF23) levels with tubular phosphate reabsorption
(r¼0.48, Po0.001).
Table 3 | Factors associated with fibroblast growth factor 23:
multivariate regression analysis using FGF23 levels as
dependent variable
Independent variables b-coefficient s.e. t P R2
Phosphate (mmol/l) 479.1 101.2 4.74 o0.001 0.64
eGFR (ml/min per 1.73m2) 2.6 0.77 3.39 0.002
1,25(OH)2D3 (mg/l) 3.2 1.40 2.30 0.03
PTH (ng/l) 0.3 0.15 1.91 0.06
Abbreviations: eGFR, estimated glomerular filtration rate (expressed as ml/min per
1.73m2); FGF23, fibroblast growth factor 23; PTH, parathyroid hormone;
1,25(OH)2D3, 1,25-dihydroxyvitamin D.
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our pediatric cohort this association could be confirmed.
Similar to other authors, we could find a significant negative
correlation between 1,25-dihydroxyvitamin D and FGF23
levels. In addition, it is shown by Saito et al.28 that FGF23 is
regulated by 1,25-dihydroxyvitamin D levels as well, which
can perform a negative feedback mechanism to reduce the
further production of activated vitamin D. To what extent the
increase in FGF23 levels is influenced by the routine
treatment with calcitriol in some of our patients remains
unclear.
In our study, we could find a relatively high rate of
25-hydroxyvitamin D deficiency, the storage form of vitamin
D, and substrate for renal 1-a-hydroxylase, in children with
CKD stage 4 and 5. Recent data support this finding.29 This
fact might have influenced the suppression of 1,25-dihydrox-
yvitamin D as well.
A deficiency of 1,25-dihydroxyvitamin D and excessively
elevated FGF23 levels seem to be associated with increased
mortality in CKD patients. The most relevant determinant of
mortality in these patients, irrespective of other biochemical
changes, seems to be hyperphosphatemia.18 It is important to
consider that serum phosphate levels in chronic renal diseases
can be influenced by multiple factors such as dietary intake,
use of phosphate-binding medication, and abnormal skeletal
conditions. If used for risk assessment, serum phosphate
levels can be misleading, especially when phosphate levels are
within the normal range.
Recent studies have suggested that under normopho-
sphatemic conditions, FGF23 may be a better biomarker for
risk assessment.21 The pathological importance and prog-
nostic significance of increased serum levels of FGF23 need
additional studies. Particularly, its influence on long-term
outcome in pediatric patients with CKD is still not well
understood. In this context, the impact of FGF23 as a
prognostic factor for growth failure and renal osteodystrophy,
for cardiovascular morbidity, and for the progression of renal
failure should be evaluated.
The development of secondary hyperparathyroidism has
an important role in the pathophysiology of chronic kidney
disease–mineral and bone disease. Its influence on cardio-
vascular morbidity due to increased vascular calcification is
evident.30 Moreover, elevated FGF23 levels have been
suggested to be an important predictor of future secondary
hyperparathyroidism in patients on hemodialysis.31 Hyper-
phosphatemia and reduced circulating levels of 1,25-dihy-
droxyvitamin D contribute to elevation of PTH levels.
This study confirms the finding that FGF23 levels are
positively correlated with PTH levels. In contrast, in the
multivariate analysis this effect is no longer significant, but
tends to show a significant association (P¼ 0.06). This likely
is a reflection of the influence of phosphate level on PTH.
Nevertheless, our data support the hypothesis that there
might be a co-regulation of PTH and FGF23 in children as
well.24 Clearly, this aspect deserves further studies.
Similar to FGF23 levels, serum PTH levels are negatively
correlated with tubular phosphate reabsorption and positively
correlated with phosphate levels. Recent human and animal
studies suggested that FGF23 and PTH act independently
regarding their phosphaturic effect. In addition, there might
be a different biological effect of these phosphatonins on
the IIa and IIc sodium phosphate co-transporter (NaPi2a/
NaPi2c) in the renal proximal tubules.2,7
In summary, in this study we show for the first time that
FGF23 is increased also in children with CKD. As in adult
patients, there occurs a gradual increase in FGF23 with the
decrease in glomerular filteration rate in chronic renal failure.
An increase in FGF23 can be shown in CKD stage 3, whereas
phosphate levels first increase in CKD stage 4. Thus, FGF23
elevation seems to precede hyperphosphatemia.
FGF23 seems to suppress the production of activated
vitamin D in children with CKD, as suggested by the inverse
correlation between FGF23 and 1,25-dihydroxyvitamin D
levels. Thus, FGF23 must be regarded as a potential uremic
toxin in children, when losing its hyperphosphaturic action
secondary to a decreasing number of viable nephrons in renal
failure.
In consequence, the PTH levels increase and can further
aggravate chronic kidney disease–mineral and bone disease,
and also influence cardiovascular morbidity already in chil-
dren.32 This positive correlation of hyperparathyroidism with
FGF23 serum levels could be reproduced in our pediatric cohort
as well. Further studies into FGF23 physiology are needed to
clarify its role in the pathogenesis of renal osteodystrophy,
including growth failure in pediatric CKD patients.
In conclusion, FGF23 is a novel and important biomarker
in children with chronic renal failure. It might be an early
indicator of and contributor to uncontrolled calcium and
phosphate homeostasis with its consecutive negative effect on
bone disease, growth failure, and cardiovascular morbidity.
MATERIALS AND METHODS
Study population
We recruited 69 children with CKD from the outpatient clinic
of the Department of Pediatric Nephrology, University
Medical Center, Hamburg-Eppendorf, Germany. Almost all
pediatric CKD patients attending our outpatient department
during the study period were included. Blood samples were
drawn and serum was stored at 301C until analysis. Written
consent was obtained from all patients and their parents, and
samples were stored as approved by the local ethics
committee. Ten children with normal renal function admitted
to a minor surgery served as controls (mean age 12.5 (±4.1)
years (range 3.7–16.8 years)), as published normal values refer
to a different assay.33 No data are available regarding the
influence of age or pubertal stage on FGF23 levels.
Patient characteristics including relevant medication are
shown in Table 1. Of the 69 patients with CKD, 45 (65%)
were male and 24 (35%) were female. The mean (s.d.) age
was 10.2 (±5.3) years (range 3 months to 17.9 years).
The etiology of CKD was congenital anomalies of kidneys
and the urinary tract (hypodysplasia, urethral valves,
prune belly syndrome) in 20 patients (28%), congenital
204 Kidney International (2010) 78, 200–206
or ig ina l a r t i c l e M van Husen et al.: FGF23 in children with CKD
nephropathies (cystinosis, focal segmental glomerulosclerosis,
syndromes) in 12 patients (17%), glomerulonephritis in 11
patients (16%), hemolytic uremic syndrome in 5 patients
(7%), cystic renal diseases (autosomal-recessive polycystic
kidney disease, autosomal-dominant polycystic kidney dis-
ease, nephronophthisis) in 13 patients (19%), and other
renal diseases in 9 (13%) patients. In all, 11 children were
treated with hemodialysis and 14 with peritoneal dialysis;
16 of the dialysis patients showed a residual glomerular
filtration rate.
In the treatment of chronic kidney disease–mineral and
bone disease, we adhere to the ‘KDOQI Clinical Practice
Guidelines for Bone Metabolism and Disease in Children
With Chronic Kidney Disease’.34 In our cohort, 26 of 69
(38%) patients received 1000 IU/day 25-hydroxyvitamin D
and 37 (54%) patients were treated with calcitriol. Phosphate
binders were used in 20 (29%) patients, calcium carbonate in
7 (10%) patients, and sevelamer in 13 (19%) patients.
CKD classification
eGFR was calculated individually using the Schwartz for-
mula.35 A classification into CKD class 1–5 was performed
according to The National Kidney Foundation Kidney Disease
Outcome Quality Initiative (NKF K/DOQI) Guidelines.36
Biochemical analysis
Routine serum biochemistry for phosphate, calcium, creatinine
and urinary electrolytes, and urinary creatinine was assessed by
standard methods at the Department of Clinical Chemistry,
University Medical Center, Hamburg-Eppendorf. PTH levels
were analyzed for biointact PTH (1–84) measured by an
automated chemiluminescence immunoassay system (DiaSorin,
Saluggia, Italy). 25-hydroxyvitamin D levels were measured
by a chemiluminescence immunoassay system (Roche, Basel,
Switzerland) and 1,25-dihydroxyvitamin D levels by a radio
immunoassay using a kit from Diasorin. Serum intact FGF23
concentrations were measured by a second-generation, two-
site, monoclonal antibody ELISA (Kainos Laboratories
International, Tokyo, Japan). This assay has earlier been
shown to recognize the biologically active, intact FGF23.37
Statistical analysis
All statistical analyses were performed using SPSS software,
version 13 (SPSS, Chicago, IL, USA).
Parametric or non-parametric tests and multivariate
analysis were used as appropriate. For all analyses, a P-value
o0.05 was considered to be statistically significant.
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